Myeloma-Developing Regimens Using Genomics (MyDRUG)
Status:
Recruiting
Trial end date:
2024-02-10
Target enrollment:
Participant gender:
Summary
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted
to affect specific genes that are mutated as part of the disease. Mutations in genes can lead
to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of
the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled
to one of the treatment arms. These arms have treatments specifically directed to the mutated
genes. Patients that do not have a greater than 25% mutation to the genes listed can be
enrolled to a non-actionable treatment arm.
The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002
study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related
Plasma Cell Malignancies. (NCT02884102).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Multiple Myeloma Research Consortium Multiple Myeloma Research Foundation
Collaborators:
AbbVie Celgene Corporation Eli Lilly and Company Genentech, Inc. GlaxoSmithKline Janssen, LP Karyopharm Therapeutics Inc Multiple Myeloma Research Consortium Takeda